Eligible participants were aged 6–11 years with at least one elexacaftor–tezacaftor–ivacaftor-responsive CFTR variant, FEV1 % predicted of 60% or higher, and stable cystic fibrosis as determined by investigators. This evidence concerns the gene CFTR and cystic fibrosis.